Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN, ASPIRIN AND CAFFEINE vs MYAMBUTOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen: weak COX-1/2 inhibitor, analgesic and antipyretic through central action; Aspirin: irreversible COX-1/2 inhibitor, anti-inflammatory, analgesic, antipyretic, antiplatelet; Caffeine: adenosine receptor antagonist, CNS stimulant, enhances analgesic effect.
Inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis of mycobacteria, leading to inhibition of cell growth.
FDA-approved: Temporary relief of minor aches and pains (headache, muscle ache, toothache, backache, menstrual cramps), reduction of fever.,Off-label: None commonly accepted.
Treatment of pulmonary tuberculosis in combination with other antituberculosis agents,Treatment of extrapulmonary tuberculosis
1-2 tablets (250 mg acetaminophen, 250 mg aspirin, 65 mg caffeine per tablet) orally every 4-6 hours as needed for pain or fever; maximum 8 tablets per 24 hours.
15-25 mg/kg orally once daily (max 2.5 g/day); usual dose 20 mg/kg/day.
Acetaminophen: 2-4 hours (prolonged in liver disease); aspirin: 15-20 minutes (active metabolite salicylate: 2-3 hours at low doses, prolonged to 15-30 hours at high doses); caffeine: 3-6 hours (prolonged in pregnancy, liver disease).
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 7-15 hours in renal impairment.
Acetaminophen: primarily hepatic via glucuronidation (UGT1A1, UGT1A6, UGT1A9), sulfation (SULT1A1), and minor CYP2E1 (toxic metabolite NAPQI); Aspirin: hydrolyzed to salicylate, further metabolized by conjugation (glycine, glucuronic acid) and oxidation; Caffeine: hepatic via CYP1A2 (major), CYP2E1, CYP3A4, N-acetyltransferase.
Partially metabolized in the liver via dealkylation to an aldehyde intermediate, which is further oxidized to a dicarboxylic acid. Approximately 50% of the drug is excreted unchanged in urine.
Acetaminophen: renal elimination of metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate 8%, unchanged 2%); aspirin: renal elimination of salicylate and metabolites (75% salicyluric acid, 10% glucuronides, 10% salicylate); caffeine: renal elimination of metabolites (paraxanthine, theobromine, theophylline; <3% unchanged). Total: >95% renal.
Renal: 50% unchanged drug; 20% as metabolite (ethambutol carboxylic acid); 15% as aldehyde intermediate; 15% unknown; fecal: <10%.
Acetaminophen: 10-25% (albumin); aspirin: 80-90% (albumin, decreased at high doses); caffeine: 35% (albumin).
20-30% bound to albumin.
Acetaminophen: 0.9-1.0 L/kg; aspirin: 0.15-0.2 L/kg (low); caffeine: 0.6-0.8 L/kg. Reflects distribution into total body water.
1.6 L/kg; distributes widely into tissues, including erythrocytes and cerebrospinal fluid (with inflamed meninges).
Acetaminophen: oral 85-98%; aspirin: oral 50-80% (due to first-pass hydrolysis); caffeine: oral ~100%.
Oral: approximately 80% absorbed.
Contraindicated in severe renal impairment (Cr Cl <10 m L/min). For Cr Cl 10-50 m L/min: avoid aspirin component; consider alternative therapy. For Cr Cl >50 m L/min: no adjustment needed for acetaminophen; aspirin may require dose reduction or monitoring.
Cr Cl 30-60 m L/min: 15-20 mg/kg daily; Cr Cl 10-29 m L/min: 15 mg/kg every 24-36 hours; Cr Cl <10 m L/min: 15 mg/kg every 48 hours.
Child-Pugh A: caution with acetaminophen (max 2 g/day) and avoid caffeine if severe. Child-Pugh B: avoid aspirin; reduce acetaminophen dose (max 2 g/day) and limit caffeine. Child-Pugh C: contraindicated due to aspirin and acetaminophen risk.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment.
Not recommended for children <12 years due to aspirin risk of Reye's syndrome. For adolescents ≥12 years: same as adult dosing: 1-2 tablets every 4-6 hours, max 8 tablets/24 hours.
15-25 mg/kg orally once daily (max 1 g/day for children weighing <20 kg, otherwise 2.5 g/day).
Caution due to increased sensitivity to aspirin (GI bleeding, renal impairment) and caffeine (insomnia, tachycardia). Start at low end of dosing: 1 tablet every 6 hours; monitor renal function and avoid long-term use.
Consider reduced initial dose based on renal function; monitor for optic neuritis.
Reye syndrome warning: Aspirin should not be used in children or teenagers with viral illnesses due to risk of Reye syndrome.
MYAMBUTOL may cause optic neuritis and decreased visual acuity, which may be dose-related and reversible upon discontinuation. Not recommended for use in children under 13 years of age.
Hepatotoxicity (acetaminophen overdose), gastrointestinal bleeding (aspirin), Reye syndrome (aspirin in children with viral illness), cardiovascular risk (aspirin may increase bleeding), caffeine-related CNS stimulation, risk of dependence.
Optic neuritis (monitor visual acuity and color discrimination); hepatic toxicity; renal impairment (dose adjustment required); interaction with aluminum-containing antacids (decreased absorption).
Hypersensitivity to any component; active peptic ulcer disease; bleeding disorders; severe hepatic impairment; children/adolescents with viral illness (Reye syndrome); third trimester of pregnancy (aspirin); concurrent use of other salicylates or NSAIDs; severe renal impairment.
Hypersensitivity to ethambutol; optic neuritis (unless benefit outweighs risk); children under 13 years of age (relative contraindication).
Alcohol increases risk of hepatotoxicity with acetaminophen and GI bleeding with aspirin. Caffeine-containing foods or beverages should be limited to avoid excessive caffeine intake. High-tyramine foods (e.g., aged cheeses, cured meats) may potentiate caffeine effects; no significant interaction documented.
No significant food interactions. However, administration with food may reduce gastrointestinal upset. Concurrent use with aluminum-containing antacids may decrease absorption; separate by at least 2 hours.
First trimester: Aspirin is associated with increased risk of neural tube defects and cardiac malformations; acetaminophen is considered low risk but some studies suggest possible association with gastroschisis. Second trimester: Aspirin may increase risk of intracranial hemorrhage; acetaminophen and caffeine generally not linked to major malformations. Third trimester: Aspirin use is contraindicated due to risk of premature ductus arteriosus closure and oligohydramnios; high-dose acetaminophen may cause oligohydramnios; caffeine metabolism slows, but moderate intake appears safe; chronic high-dose caffeine may be associated with low birth weight.
Ethambutol (Myambutol) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. Human data are limited but do not suggest a significant increase in major malformations. However, due to the risk of optic neuritis in the mother, use during pregnancy should be cautious and only if clearly needed.
Acetaminophen: M/P ratio approximately 0.9; small amounts excreted; considered safe. Aspirin: M/P ratio variable, typically 0.12-0.42; avoid high doses due to risk of Reye's syndrome; single doses unlikely harmful. Caffeine: M/P ratio approximately 0.5-1.0; moderate intake (≤300 mg/day) considered safe; excessive intake may cause irritability in infant.
Ethambutol is excreted into human breast milk in low concentrations; the estimated infant dose is approximately 2-4% of the maternal weight-adjusted dose. The milk-to-plasma ratio is approximately 0.57. The American Academy of Pediatrics considers ethambutol compatible with breastfeeding. Monitor the infant for signs of optic neuritis or gastrointestinal effects.
Acetaminophen: No dose adjustment needed; standard dosing (650-1000 mg every 4-6 hours, max 3000 mg/day). Aspirin: Avoid doses >81 mg/day in third trimester; use lowest effective dose. Caffeine: Metabolism prolonged; limit to ≤200 mg/day (approximately 2 cups coffee).
No specific dose adjustments are routinely recommended during pregnancy. However, pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced renal clearance) may reduce serum concentrations; therapeutic drug monitoring is not standard but may be considered. Adjust dose based on renal function; usual dose is 15-25 mg/kg/day, not to exceed 2.5 g/day.
Acetaminophen, aspirin, and caffeine combination is used for mild to moderate pain and fever reduction. Aspirin component provides anti-inflammatory effects; caution in patients with bleeding disorders or those on anticoagulants due to increased bleeding risk. Acetaminophen hepatotoxicity risk with doses >4g/day or in liver disease. Caffeine may cause insomnia, tremor, or palpitations; avoid in patients with anxiety disorders. Reye syndrome risk with aspirin use in children with viral illnesses. Monitor renal function in elderly or dehydrated patients.
MYAMBUTOL (ethambutol) is a bacteriostatic agent used primarily in combination therapy for tuberculosis. Monitor for optic neuritis, which can cause decreased visual acuity, color blindness, and visual field defects; baseline and monthly visual acuity and color discrimination tests are mandatory. Dose adjustments required in renal impairment (Cr Cl <30 m L/min). Avoid in children <13 years old due to inability to monitor vision. May cause hyperuricemia; monitor uric acid levels in patients with gout.
Do not exceed recommended dose; acetaminophen overdose can cause liver damage.,Avoid alcohol while taking this medication.,Do not use in children or teenagers with viral illnesses due to Reye syndrome risk.,May cause stomach upset; take with food or milk.,Limit caffeine intake from other sources when using this medication.
Take exactly as prescribed, usually once daily, with or without food.,Report any changes in vision immediately, such as blurred vision, difficulty seeing colors, or blind spots.,Avoid consuming alcohol; may increase risk of liver toxicity.,Do not stop taking this medication even if you feel better; complete full course to prevent resistance.,This drug may cause numbness or tingling in hands or feet; report these symptoms.,Inform your doctor if you have kidney disease, gout, or eye problems before starting treatment.
"Triamterene, a potassium-sparing diuretic, can inhibit the hepatic metabolism of caffeine by competing for cytochrome P450 (CYP) 1A2, the primary enzyme responsible for caffeine clearance. This leads to increased plasma caffeine concentrations and prolonged caffeine half-life, potentially causing caffeine toxicity manifesting as nervousness, insomnia, tachycardia, and diuresis enhancement. Patients may experience exaggerated stimulant effects and increased risk of cardiac arrhythmias when combining these agents."
"Caffeine inhibits the metabolism of sulfadiazine by competitively antagonizing cytochrome P450 (CYP) enzymes, particularly CYP1A2, leading to increased plasma concentrations of sulfadiazine. This elevates the risk of dose-dependent adverse effects, including crystalluria, nephrotoxicity, and hypersensitivity reactions. The interaction may also reduce the therapeutic efficacy of sulfadiazine due to altered pharmacokinetics."
"Caffeine inhibits the cytochrome P450 enzyme CYP2C9, which is primarily responsible for the metabolism of losartan to its active metabolite E-3174. This inhibition can lead to increased plasma concentrations of losartan and decreased formation of the active metabolite, potentially reducing losartan's antihypertensive efficacy. The clinical outcome may be suboptimal blood pressure control in patients consuming high amounts of caffeine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN, ASPIRIN AND CAFFEINE vs MYAMBUTOL, answered by our medical review team.
ACETAMINOPHEN, ASPIRIN AND CAFFEINE is a NSAID / Antiplatelet that works by Acetaminophen: weak COX-1/2 inhibitor, analgesic and antipyretic through central action; Aspirin: irreversible COX-1/2 inhibitor, anti-inflammatory, analgesic, antipyretic, antiplatelet; Caffeine: adenosine receptor antagonist, CNS stimulant, enhances analgesic effect.. MYAMBUTOL is a Antitubercular Agent that works by Inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis of mycobacteria, leading to inhibition of cell growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN, ASPIRIN AND CAFFEINE and MYAMBUTOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN, ASPIRIN AND CAFFEINE is: 1-2 tablets (250 mg acetaminophen, 250 mg aspirin, 65 mg caffeine per tablet) orally every 4-6 hours as needed for pain or fever; maximum 8 tablets per 24 hours.. The standard adult dose of MYAMBUTOL is: 15-25 mg/kg orally once daily (max 2.5 g/day); usual dose 20 mg/kg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN, ASPIRIN AND CAFFEINE and MYAMBUTOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN, ASPIRIN AND CAFFEINE is classified as Category D/X. First trimester: Aspirin is associated with increased risk of neural tube defects and cardiac malformations; acetaminophen is considered low risk but some studies suggest possible . MYAMBUTOL is classified as Category C. Ethambutol (Myambutol) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. Human data are limited but do not suggest a significant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.